


IL-13 is a Dominant Cytokine in the Pathophysiology of AD^{1,2}

There are **three approved biologics** that target IL-13 signaling.³⁻⁵

Dupilumab³
Targets the IL-4 α Receptor

Lebrikizumab-Ibkz⁴
Targets the IL-13 Cytokine

Tralokinumab-Idrm⁵
Targets the IL-13 Cytokine



All three therapeutic antibodies differ in their binding affinity, dissociation constant, potency, and half-life.^{4,10,14-17}

To learn more about the role of IL-13 in AD, click below

Explore

Access US Prescribing Information at the following URLs:

DUPIXENT®: https://www.regeneron.com/downloads/dupilumab_fpi.pdf

EBGLYSS®: <https://pi.lilly.com/us/ebglyss-uspi.pdf>

ADBRY®: <https://www.leo-pharma.us/adbrypi>

AD=Atopic Dermatitis; **IL**=Interleukin; **IL-4Ra**=Interleukin-4 Receptor Alpha; **IL-13Ra1**=Interleukin-13 Receptor Alpha 1; **IL-13Ra2**=Interleukin-13 Receptor Alpha 2.

1. Tsoi LC, et al. *J Invest Dermatol.* 2019;139(7):1480-1489. **2.** He H, et al. *J Allergy Clin Immunol.* 2021;147(1):199-212. **3.** DUPIXENT® [US PI]. Tarrytown, NY, USA: Regeneron Pharmaceuticals, Inc., 2024. **4.** EBGLYSS® [US PI] Indianapolis, IN, USA: Eli Lilly USA LLC, 2024. **5.** ADBRY® [US PI]. Madison, NJ: LEO Pharma Inc., 2024. **6.** Matsunaga K, et al. *Allergol Int.* 2020;69:187-196. **7.** Kasaian MT, et al. *J Pharmacol Exp Ther.* 2008;325:882-892. **8.** Simpson EL, et al. *J Am Acad Dermatol.* 2018;78(5):863-871.e11. **9.** Gonçalves F, et al. *Drugs Context.* 2021;10:2021-1-7. **10.** Ultsch M, et al. *J Mol Biol.* 2013;425(8). **11.** Moyle M, et al. *Exp Dermatol.* 2019;28(7):756-768. **12.** Lytvyn Y, Gooderham M. *Pharmaceutics.* 2023;15(2):568. **13.** Bieber T. *Allergy.* 2020;75(1):54-62. **14.** Okragly A, et al. *Dermatol Ther (Heidelb).* 2023;13(7):1535-1547. **15.** Popovic B, et al. *J Mol Biol.* 2017;429(2):208-219. **16.** Adtralza [SmPC]. Ballerup, Denmark: LEO Pharma A/S, 2021. **17.** Dupixent EMA Assessment Report, 2017.

This content was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

Other product/company names mentioned herein are trademarks of their respective owners.

VV-MED-169573 03/2025 © 2025 Lilly USA, LLC. All Rights Reserved.